(Q28371010)

English

KRAS G12/G13

genetic variant

In more languages

Statements

Protein Altering Variant

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/77

human chromosome 12

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/77

25398280

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/77

25398285

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/77

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/77

positive therapeutic predictor for

medical condition treated

pancreatic adenocarcinoma

statement disputed by

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/990

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

negative therapeutic predictor for

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/35

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/35

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/135

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

trametinib / gemcitabine combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

pancreatic adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/622

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6293

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6294

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6295

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

3 references

22 December 2019

https://civic.genome.wustl.edu/links/evidence/134

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6296

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6363

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

cetuximab / chemotherapy combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/134

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

negative prognostic predictor for

colorectal cancer

determination method

CIViC evidence level D

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/194

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

statement disputed by

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6292

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

colorectal cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

statement disputed by

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2231

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/77

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371010&oldid=2014798297"